Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 66 patients

被引:62
作者
Ibrahim, EM
Ezzat, AA
El-Weshi, AN
Martin, JM
Khafaga, YM
Al Rabih, W
Ajarim, DS
Al-Foudeh, MO
Zucca, E
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh 11211, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia
[3] Osped San Giovanni Bellinzona, Inst Oncol Svizzera Italiana, Bellinzona, Switzerland
关键词
intestinal; non-Hodgkin's lymphoma; primary;
D O I
10.1023/A:1008389001990
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In Saudi Arabia, primary gastrointestinal non-Hodgkin's lymphoma (NHL) is common. Recently we have reported one of the largest series of primary gastric (PG) diffuse large B-cell lymphoma (DLCL). This has prompted the analysis of another series of patients with primary intestinal DLCL to depict the clinical features and the outcome of that disease and to compare those with that for PG involvement. Patients and methods: The data of 66 adult patients with primary intestinal NHL having DLCL histology were retrospectively reviewed. Results: Patients had a median age of 45 years. Of 64 treated patients, 16% and 84% received single and multiple modality treatment, respectively. Seventy-six percent, ten percent, and fourteen percent attained complete remission (CR), partial remission (PR), and no response/progressive disease, respectively. Multivariate analysis failed to identify any variable that predict the likelihood of attaining CR. Over a median follow-up of 81 months for all 66 patients, 32 (48%) were alive and disease-free, 5 (8%) were alive with evidence of disease, and the remaining 29 (44%) were dead. The median overall survival (OS) was 101 months and it was 58% (+/- 6%) and 48% (+/- 7%) at 5- and 10-year, respectively. Of the 54 patients who achieved CR or PR, the median event-free survival (EFS) was not reached, but the predicted 5- and 10-year EFS was 61% (+/- 7%) and 52% (+/- 7%), respectively. Only low serum albumin (< 30 g/l) was associated with adverse OS and EFS in a univariate analysis, however, multivariate analysis was not possible. Our analysis showed that compared with single-modality management, multi-modality strategy attained significantly higher CR, and advantageous EFS, but without a significant superior effect on OS. In comparison with patients with PG DLCL, those with primary intestinal disease demonstrated more adverse prognostic features, but had an equivalent survival. Conclusions: This series characterized the clinico-pathologic features and outcome of patients with primary intestinal DLCL. While surgical resection in primary intestinal NHL seems beneficial, only prospective randomized studies can ascertain its precise role. Compared with patients with PG NHL, patients with primary intestinal disease had more prevalence of adverse prognostic features.
引用
收藏
页码:53 / 58
页数:6
相关论文
共 37 条
[1]  
AHMAD M, 1997, NONHODGKINS LYMPHOMA, P103
[2]  
BOBBI PG, 2000, HAEMATOLOGICA, V85, P372
[3]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[4]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[5]   SMALL INTESTINAL LYMPHOMA [J].
COOPER, BT ;
READ, AE .
WORLD JOURNAL OF SURGERY, 1985, 9 (06) :930-937
[6]  
Cox D., 1989, Analysis of Binary Data
[7]   CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC FACTORS IN EXTRANODAL NON-HODGKIN LYMPHOMAS [J].
DAMORE, F ;
CHRISTENSEN, BE ;
BRINCKER, H ;
PEDERSEN, NT ;
THORLING, K ;
HASTRUP, J ;
PEDERSEN, M ;
JENSEN, MK ;
JOHANSEN, P ;
ANDERSEN, E ;
BACH, B ;
SORENSEN, E .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (10) :1201-1208
[8]   NON-HODGKINS-LYMPHOMA OF THE GASTROINTESTINAL-TRACT - A POPULATION-BASED ANALYSIS OF INCIDENCE, GEOGRAPHIC-DISTRIBUTION, CLINICOPATHOLOGICAL PRESENTATION FEATURES, AND PROGNOSIS [J].
DAMORE, F ;
BRINCKER, H ;
GRONBAEK, K ;
THORLING, K ;
PEDERSEN, M ;
JENSEN, MK ;
ANDERSEN, E ;
PEDERSEN, NT ;
MORTENSEN, LS .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1673-1684
[9]  
Dixon W. J., 1990, BMDP STAT SOFTWARE
[10]  
DRAGOSICS B, 1985, CANCER, V55, P1060, DOI 10.1002/1097-0142(19850301)55:5<1060::AID-CNCR2820550523>3.0.CO